PIVKA-II shows promise for HCCPIVKA-II as a surrogate biomarker for therapeutic response in Non-AFP-secreting hepatocellular carcinoma.
We aimed to discover how well PIVKA-II can predict treatment response in patients with non-AFP-secreting hepatocellular carcinoma (HCC) receiving systemic therapy.
By measuring PIVKA-II levels and assessing imaging after 8-12 weeks of treatment, we found a connection between PIVKA-II levels, tumor size, and treatment outcomes.
The study revealed a promising “50-50 rule” that can indicate prognosis based on PIVKA-II changes, making it a valuable marker for HCC treatment success.
Antitumor properties
Most Useful Review
4 people found this helpful
K2 MK7 assists in the normal absorption of calcium and the strengthening of bones, as well as supports the maintenance of cardiovascular and nervous systems. At doses of D3 exceeding 5000 IU, it is crucial to take vitamin K2 MK7. Some substances essential for our body can only be synthesised with menaquinone. Vitamin K2 is recognised for its benefits in various bodily systems: it promotes cardiovascular health by directing calcium from the bloodstream to bone tissue, regulating bone density and blood clotting. Research has revealed that vitamin K2 can slow down, or even halt, cancer cell activity, showing positive effects on lung, pancreatic, bladder, and rectal cancers.